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Histone deacetylases (HDACs) play an important role in the
epigenetic control of gene expression in both normal and
cancer cells. Previous studies have demonstrated that
pharmaceutical inhibition of HDACs can kill and/or
suppress the growth of cancer cells. RG2833 is a HDAC
inhibitor that targets specific HDACs known to be active in
cancer cells. Melanoma cells have previously been shown
to respond to HDAC inhibitors that are structurally similar
to RG2833. We hypothesized that the inhibition of HDAC
activity by RG2833 would result in the reduced growth
and/or death of cells from the malignant melanoma
cell lines SK-MEL-5 and SK-MEL-28. To test our
hypothesis, we exposed SK-MEL-5 and SKMEL-28 cells to
increasing concentrations of RG2833. We found that
concentrations of RG2833 that effectively inhibited HDAC
activity also resulted in reduced melanoma cell growth and
viability. These results demonstrate the effectiveness of
RG2833 in reducing the growth and viability of malignant
melanoma cells in vitro and warrant further investigation
of the potential therapeutic use of RG2833 and related
compounds in the battle against cancer.
HDAC Inhibitor. HDAC1 and HDAC3 inhibitor RG2833
(Figure 1) was obtained from Selleck Chemicals (Houston,
TX).
HDAC Activity Assay:
• Cayman Chemical: HDAC Cell-Based Activity Assay Kit
• Performed in live cells
• Evaluated HDAC inhibition at varying RG2833 concentrations
NCI-60 Assay / Sulforhodamine B (SRB) Assay:
• Measure relative number of cells by staining total protein
• Assay used by National Cancer Institute to screen potential
anti-cancer compounds
CellTiter-GloTM Viability Assay:
• Determined cell viability based on amount of ATP and
metabolic activity
• Multiple time points
AlamarBlue® Viability Assay:
• Determined cell viability
• AlamarBlue® reagent is metabolized to colored product in
living cells
• Multiple time pointsAnticancer therapeutic studies targeting histone
deacetylase inhibitors have shown promise in the
suppression of cancer cell growth (Pan 2007; Boyle 2005;
Munshi 2005). When histone tails are acetylated, the
association between histones and DNA is loosened, and the
DNA is more accessible to the transcriptional machinery.
Histone deacetylases (HDAC) remove acetyl groups from
histone tails, thereby tightening the association between
DNA and histones (Dokmanovic et al. 2007). HDAC
inhibitors promote acetylation by blocking HDAC activity.
Cancer cell growth can be suppressed by HDAC inhibitors
because of their effects on gene expression (Munshi et al.
2014). RG2833 is a recently developed HDAC inhibitor
capable of penetrating the blood-brain barrier (Sandi et al.
2011).
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Figure 1: Molecular 
Structure of RG2833
Figure 2: Phase-contrast images of SK-MEL-5 (A) and SK-MEL-28 (B) cell lines.
Figure 3: RG2833 Inhibits HDAC Activity in SK-MEL-5 and SK-
MEL-28 cell lines. Percentages are relative to untreated control.
Numbers indicate statistically independent groups. p < 0.05
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Cell Lines and Culture: The two human malignant
melanoma cell lines SK-MEL-5 and SK-MEL-28, were
obtained from the American Type Culture Collection
(Manassas, VA). The cells were maintained under standard
cell culture conditions.
• RG2833 inhibited HDAC activity in SK-MEL-5 and SK-
MEL-28 cells in vitro
• Concentrations of RG2833 that most effectively
inhibited HDAC activity also reduced cell growth and
viability of both cell lines
• We observed significant variability in results based on
the the assay used.
NCI-60 / SRB Assay (48 Hours):
Figure 4: Suppression of SK-MEL-5 and SK-MEL-28 growth is
observed following treatment with 10uM RG2833 for 48 h.
Numbers indicate statistically independent groups (p < 0.05).
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Alamar Blue® Viability Assay (48 Hours):
Figure 6: Viability of SK-MEL-5 cells is reduced following
treatment with 10uM RG2833 for 48 h. Note: SK-MEL-28 viability
was significantly reduced with 10uM RG2833 at 72 h (not shown).
Numbers indicate statistically independent groups (p < 0.05).
Future Research
• Analyze gene expression using Real-Time RT-PCR
• Qiagen RT2 Profiler Array: Human Cancer Drug
Targets
• Follow-up analysis of protein expression for select
signaling pathways
• Introduce RG2833 to a control melanocyte cell line
http://ruo.mbl.co.jp/g/product/cyclex/cellular-acetyle.html
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CellTiter-GloTM Viability Assay (48 Hours):
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Figure 5: Decreased viability of SK-MEL-5 and SK-MEL-28 cells
is observed following treatment with 10uM RG2833 for 48 h.
Numbers indicate statistically independent groups (p < 0.05).
